
Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) – Equities research analysts at HC Wainwright upped their Q1 2027 earnings per share estimates for Inhibikase Therapeutics in a report released on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.
Several other analysts also recently weighed in on IKT. Chardan Capital restated a “neutral” rating and set a $1.50 price objective on shares of Inhibikase Therapeutics in a research report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Inhibikase Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $4.75.
View Our Latest Stock Report on Inhibikase Therapeutics
Inhibikase Therapeutics Trading Down 4.8%
Shares of IKT opened at $1.38 on Monday. Inhibikase Therapeutics has a 52-week low of $1.37 and a 52-week high of $2.61. The business’s fifty day moving average is $1.85 and its 200-day moving average is $1.93.
Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01.
Institutional Investors Weigh In On Inhibikase Therapeutics
A number of institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in Inhibikase Therapeutics during the third quarter worth $14,323,000. Goldman Sachs Group Inc. grew its holdings in Inhibikase Therapeutics by 96.4% in the third quarter. Goldman Sachs Group Inc. now owns 98,534 shares of the company’s stock worth $202,000 after purchasing an additional 48,364 shares during the period. Soleus Capital Management L.P. increased its stake in Inhibikase Therapeutics by 3.2% in the third quarter. Soleus Capital Management L.P. now owns 11,225,000 shares of the company’s stock valued at $23,067,000 after purchasing an additional 350,000 shares in the last quarter. Alps Advisors Inc. increased its stake in Inhibikase Therapeutics by 37.0% in the third quarter. Alps Advisors Inc. now owns 183,550 shares of the company’s stock valued at $377,000 after purchasing an additional 49,548 shares in the last quarter. Finally, Abel Hall LLC raised its holdings in shares of Inhibikase Therapeutics by 15.0% during the third quarter. Abel Hall LLC now owns 53,311 shares of the company’s stock valued at $110,000 after purchasing an additional 6,959 shares during the period. Institutional investors own 3.81% of the company’s stock.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Featured Articles
- Five stocks we like better than Inhibikase Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
